ESPR reports a wider-than-expected loss for the third quarter of 2024. Revenues also lag estimates. Stock down in pre-market trading.

ADM announces preliminary results for the third quarter of 2024. The Nutrition business witnesses lower-than- expected results due to the weaker...

SIRI's third-quarter 2024 results reflect weakness in subscriber, advertisement and other revenues.

SIRI's third-quarter 2024 results reflect weakness in subscriber, advertisement and other revenues.

UTHR reports better-than-expected results in third-quarter 2024 on the back of strong demand for its treprostinil medications, especially Tyvaso.

ROKU's third-quarter 2024 results benefit from consistent growth in streaming households and streaming hours on The Roku Channel.

LPX's third-quarter results reflect solid demand trends in the Siding business, partially offset by soft contributions from the OSB segment.

ABG reports lower-than-expected third-quarter results, wherein revenues rise year over year.

CRISPR Therapeutics reports mixed third-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is progressing well.

MRK posts better-than-expected third-quarter results. The company lowers its guidance, likely due to the soft sales performance of the Gardasil...